Virpax Pharmaceuticals

NasdaqCM:VRPX Stock Report

Mkt Cap: US$13.5m

Virpax Pharmaceuticals Past Performance

How has Virpax Pharmaceuticals performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-59.2%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: VRPX is currently unprofitable.

Growing Profit Margin: VRPX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: VRPX is unprofitable, and losses have increased over the past 5 years at a rate of 59.2% per year.

Accelerating Growth: Unable to compare VRPX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VRPX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (5%).


Return on Equity

High ROE: VRPX has a negative Return on Equity (-68.19%), as it is currently unprofitable.


Discover strong past performing companies